Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Incyte (INCY) PT Raised to $146 at BMO Capital
May 5, 2017 9:13 AM EDTBMO Capital raised its price target on Incyte (NASDAQ: INCY) to $146.00 (from $144.00) while maintaining a Outperform rating following strong Jakafi results in Q1.
Analyst M. Ian Somaiya commented, "While polycythemia vera (PV) continues to be a growth driver, graft vs host... More
Incyte (INCY) Tops Q1 EPS by 4c
May 4, 2017 7:15 AM EDTIncyte (NASDAQ: INCY) reported Q1 EPS of ($0.96), $0.04 better than the analyst estimate of ($1.00). Revenue for the quarter came in at $384.08 million versus the consensus estimate of $358.27 million.
Cash, cash equivalents and marketable securities position As of March 31, 2017, cash, cash equivalents and marketable securities... More
